# City Hill Ventures

> City Hill Ventures is a VC fund backing Biotechnology and Therapeutics. See 22 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: San Diego, United States
- Total investments: 22
- Last investment: May 2023
- Lead investor: 41%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/city-hill-ventures/about/
- X (Twitter): http://twitter.com/CityHillVC
- Website: http://cityhillventures.com

City Hill Ventures is a VC fund in San Diego focused on Biotechnology and Therapeutics. City Hill Ventures, LLC is a health care focused investment firm based in San Diego, California, one of the leading metropolitan area life science clusters in the world. City Hill Ventures makes primarily seed and early stage investments in private companies in life sciences (therapeutics, diagnostics, medical devices) and health care technology.

## Contacts

5 contacts available for City Hill Ventures. Shizune tracks 6 team members at City Hill Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/city-hill-ventures?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 11 | 50% |
| Therapeutics | 6 | 27% |
| Health Care | 5 | 23% |
| Life Science | 4 | 18% |
| Medical | 3 | 14% |

13 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 8 | 36% |
| Series A | 4 | 18% |
| Series C | 3 | 14% |
| Seed | 2 | 9% |
| Funding Round | 2 | 9% |

8 stages tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| David Anderson | Operating Partner | 0 | https://shizune.co/investors/profile/david-anderson-13 |
| Jonathan Lim | Founder | 11 | https://shizune.co/investors/profile/jonathan-lim |
| Karen Gilmore | Controller | 0 | https://shizune.co/investors/profile/karen-gilmore |
| Karen Gilmore | Controller | 0 | https://shizune.co/investors/profile/karen-gilmore-cb83 |
| Patrick O`Connor | Operating Partner | 0 | https://shizune.co/investors/profile/patrick-o-connor |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Boundless Bio | Boundless Bio is a company that develops novel cancer therapeutics intended to understand and treat intraceable cancers. It aims to be the foremost biopharma company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable cancers.Boundless Bio was founded in 2018 and isheadquartered in La Jolla, California. | $100M | Series C | May 16, 2023 |  |
| Maze Therapeutics | Maze Therapeutics is a operator of a biotechnology firm intended to focused on translating genetic insights into new medicines. The company's translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, functional genomics and an array of drug discovery approaches.andits also reveals modifier genes that confer protection and provides deeper understanding of the target biology and how these targets can be targeted with drug therapies, enabling patients with protection against diseases. | $190M | Venture - Series Unknown | Jan 10, 2022 |  |
| OncoMyx Therapeutics | OncoMyx Therapeutics develops oncolytic immunotherapies called myxoma (MYXV) to assist in creating an immune response and treat cancer. Its myxoma virus (MYXV) platform targets hematologic and solid tumors with a unique oncolytic virus called myxoma and a novel patented systemic delivery approach which can be carried systemically by humanleukocytes where it can then infect tumor cells.The company was founded in 2018 and is headquartered in Phoenix, Arizona. | $50M | Series B | Dec 09, 2021 |  |
| Viron | OncoMyx Therapeutics develops oncolytic immunotherapies based on the myxoma virus (MYXV) platform to orchestrate an immune response and treat cancer. The company's MYXV platform, is poised to be a best-in-class OV approach. The company assembled the top OV team around MYXV to advance a pipeline of oncology therapeutics for the benefit ofcancer patients. | $50M | Series B | Dec 08, 2021 |  |
| Boundless Bio | Boundless Bio is a company that develops novel cancer therapeutics intended to understand and treat intraceable cancers. It aims to be the foremost biopharma company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable cancers.Boundless Bio was founded in 2018 and isheadquartered in La Jolla, California. | $105M | Series B | Apr 28, 2021 |  |
| Erasca | Erasca develops oncology drugs intended to provide precision oncology options. The company's drugs are being developed through multiple discovery programs for undisclosed targets that are biological drivers of cancer and are pursuing additional opportunities for pipeline expansion through academic and biopharmaceutical collaborations,providing patients with new potential solutions to not just treat but cure cancer.Erasca was founded in 2018 and is headquartered in San Diego, California. | $200M | Series B | Apr 27, 2020 |  |
| Black Diamond Therapeutics | Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery and development of small-molecule. It is engaged in discovering and developing small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, Mutation-Allostery-Pharmacology, which targets cancer mutations.Black Diamondfocuses on the discovery and development of precision medicines for cancer that are directed against a novel class of allosteric mutant oncogenes. It also targets undrugged mutations in patients with genetically defined cancers for whom limited treatment options currently exist. It is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry. | $85M | Series C | Dec 05, 2019 |  |
| Maze Therapeutics | Maze Therapeutics is a operator of a biotechnology firm intended to focused on translating genetic insights into new medicines. The company's translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, functional genomics and an array of drug discovery approaches.andits also reveals modifier genes that confer protection and provides deeper understanding of the target biology and how these targets can be targeted with drug therapies, enabling patients with protection against diseases. |  |  | Oct 23, 2019 |  |
| Boundless Bio | Boundless Bio is a company that develops novel cancer therapeutics intended to understand and treat intraceable cancers. It aims to be the foremost biopharma company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable cancers.Boundless Bio was founded in 2018 and isheadquartered in La Jolla, California. | $46.4M | Series A | Sep 19, 2019 |  |
| ORIC Pharmaceuticals | ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s lead product candidate,ORIC-101, is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeuticsacross a variety of solid tumors. ORIC’s second product candidate, ORIC-533, is an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens. Beyond these two product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC’s scientific founders, Charles Sawyers, MD, and Scott Lowe, PhD, have long records of discovering novel targets in cancer that have led to innovative treatments. | $55M | Series D | Aug 09, 2019 |  |

10 of 22 investments shown.

## Co-investors
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 4 deals together
- [Boxer Capital](https://shizune.co/investors/profile/boxer-capital) — VC Fund, 4 deals together
- [Invus](https://shizune.co/investors/profile/invus) — VC Fund, 4 deals together
- [Logos Capital](https://shizune.co/investors/profile/logos-capital) — VC Fund, 4 deals together
- [Nextech Invest](https://shizune.co/investors/profile/nextech-invest) — VC Fund, 4 deals together
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 4 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does City Hill Ventures invest in?

City Hill Ventures invests primarily in Biotechnology, Therapeutics and Health Care startups, most often at Series B and Series A stage. Most of the 22 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact City Hill Ventures?

Public channels for City Hill Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at City Hill Ventures?

The team at City Hill Ventures includes David Anderson (Operating Partner), Jonathan Lim (Founder) and Karen Gilmore (Controller), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co